標(biāo)題: Titlebook: Handbuch für die Schiffsführung; Schiffahrtsrecht, La Joseph Krau? (Seefahrtschuldirektor i. R.),Martin Textbook 19596th edition Springer- [打印本頁(yè)] 作者: injurious 時(shí)間: 2025-3-21 19:29
書(shū)目名稱(chēng)Handbuch für die Schiffsführung影響因子(影響力)
書(shū)目名稱(chēng)Handbuch für die Schiffsführung影響因子(影響力)學(xué)科排名
書(shū)目名稱(chēng)Handbuch für die Schiffsführung網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱(chēng)Handbuch für die Schiffsführung網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱(chēng)Handbuch für die Schiffsführung被引頻次
書(shū)目名稱(chēng)Handbuch für die Schiffsführung被引頻次學(xué)科排名
書(shū)目名稱(chēng)Handbuch für die Schiffsführung年度引用
書(shū)目名稱(chēng)Handbuch für die Schiffsführung年度引用學(xué)科排名
書(shū)目名稱(chēng)Handbuch für die Schiffsführung讀者反饋
書(shū)目名稱(chēng)Handbuch für die Schiffsführung讀者反饋學(xué)科排名
作者: intelligible 時(shí)間: 2025-3-21 21:31 作者: expound 時(shí)間: 2025-3-22 01:27 作者: concentrate 時(shí)間: 2025-3-22 04:55
https://doi.org/10.1007/978-3-662-26780-6Chemie; Man?vrieren; Maschine; Physik; Seerecht; Stabilit?t作者: unstable-angina 時(shí)間: 2025-3-22 09:04 作者: atrophy 時(shí)間: 2025-3-22 14:06 作者: 愛(ài)好 時(shí)間: 2025-3-22 20:19 作者: 滑動(dòng) 時(shí)間: 2025-3-22 21:20
Springer-Verlag Berlin Heidelberg 1959作者: 誰(shuí)在削木頭 時(shí)間: 2025-3-23 05:05 作者: 繼而發(fā)生 時(shí)間: 2025-3-23 05:46 作者: 成份 時(shí)間: 2025-3-23 09:59
Seemannschaft,n h?nge die Fahrt- und Man?vriertabelle im Kartenhaus an gut sichtbarer Stelle aus, damit jeder neu an Bord kommende Nautiker einen Anhalt über die Man?vriereigenschaften des Schiffes hat. Auch das von der SBG und der HSVA herausgegebene Man?vrierbuch sollte geführt werden. Die einzelnen Man?ver sol作者: 鳴叫 時(shí)間: 2025-3-23 14:04
,Einiges aus der Stabilit?tslehre,eschiff mu? aber nicht nur genügende Stabilit?t besitzen, sondern es soll bei Seegang auch m?glichst weiche und angenehme Bewegungen ausführen. Für das Vorhandensein genügender Stabilit?t ist in erster Linie die Bauwerft verantwortlich, für die Handigkeit eines Frachtschiffes in schwerer See in weit作者: 軟弱 時(shí)間: 2025-3-23 21:17 作者: 乞丐 時(shí)間: 2025-3-24 02:04 作者: Pepsin 時(shí)間: 2025-3-24 04:48
Signal und Funkwesen,euestem Anhang (Amtliche Liste der Seeschiffe) und den dazugeh?rigen Signalflaggen sowie eine Morsesignallampe an Bord haben. Schiffe bis zu 250 BRT sind für Fahrten innerhalb der Nord- oder Ostsee von der Mitführung des Signalbuches und der Signalflaggen und solche bis zu 150 BRT von der Mitführung作者: Hallmark 時(shí)間: 2025-3-24 06:39 作者: –DOX 時(shí)間: 2025-3-24 11:54 作者: prosperity 時(shí)間: 2025-3-24 16:26 作者: 繼而發(fā)生 時(shí)間: 2025-3-24 19:16 作者: 有雜色 時(shí)間: 2025-3-24 23:30 作者: 不容置疑 時(shí)間: 2025-3-25 06:04
gainst several kinds of cancer in Japan. All of them are derived from mushrooms, and about 25?years has passed since their clinical approval. Since their mechanisms of action have become elucidated basically and clinically by many investigators, they are discussed here from an immunological point of作者: FLUSH 時(shí)間: 2025-3-25 08:20
Joseph Krau?,Martin Berger,Walter Helmers exert potent cytotoxicity against a variety of cancer cells irrespective of MHC class I expression, and bridge innate and adaptive immunity. They comprise 1–5?% of peripheral blood mononuclear cell (PBMC); the majority of them express the Vγ9Vδ2 T cell receptor that recognizes phosphoantigens. Ther作者: 斜谷 時(shí)間: 2025-3-25 13:35 作者: DECRY 時(shí)間: 2025-3-25 18:10 作者: 得意牛 時(shí)間: 2025-3-25 22:04 作者: Anonymous 時(shí)間: 2025-3-26 02:29 作者: 領(lǐng)巾 時(shí)間: 2025-3-26 06:07 作者: TOM 時(shí)間: 2025-3-26 09:52 作者: GIST 時(shí)間: 2025-3-26 14:14 作者: Conserve 時(shí)間: 2025-3-26 18:59
Joseph Krau?,Martin Berger,Walter Helmerslls that are harmful for host’s survival. Immunosurveillance, is a process by which immune system monitors the cells/tissues continuously and eliminates the modified or transformed cells. While the immune cells have unique abilities to detect the abnormally dividing cells, tumors also develop specia作者: nitric-oxide 時(shí)間: 2025-3-26 20:59
Joseph Krau?,Martin Berger,Walter Helmersr in the ‘melanoma’ series covers different treatment approaches recommended by clinicians for the management of melanoma. A brief history of how melanoma treatment evolved during 19th and 20th centuries is discussed before going into the details of currently used approaches. Surgery, the standard t作者: 顛簸地移動(dòng) 時(shí)間: 2025-3-27 03:17
Joseph Krau?,Martin Berger,Walter HelmersFDA both as an adjuvant therapy for surgically-treated ‘high-risk’ melanoma patients and as primary treatment for unresectable metastatic melanoma patients. It is a monoclonal antibody against CTLA-4, a negative regulatory receptor on T-cells. The current chapter describes potential benefits of CTLA作者: harangue 時(shí)間: 2025-3-27 07:49
foreign organisms inside the host. In addition to providing protection from foreign organisms, immune system also functions in identifying abnormal cells of the host such as cancer cells and prevents the development of cancers. In this chapter a detailed overview of immune system is presented. First作者: 淡紫色花 時(shí)間: 2025-3-27 10:29 作者: hazard 時(shí)間: 2025-3-27 17:08
Joseph Krau? (Seefahrtschuldirektor i. R.),Martin 作者: atrophy 時(shí)間: 2025-3-27 21:39 作者: Cerebrovascular 時(shí)間: 2025-3-28 00:58
Joseph Krau?,Martin Berger,Walter Helmers underwent extensive proliferation under these conditions. Such cultured Vγ9Vδ2 T cells retained cytokine secretion capacity and mediated cytotoxicity against a variety of cancer cell lines. Recently, we conducted phase I clinical studies to evaluate safety and potential antitumor effects of intrave作者: 全部 時(shí)間: 2025-3-28 03:50 作者: 擔(dān)心 時(shí)間: 2025-3-28 07:38 作者: 結(jié)束 時(shí)間: 2025-3-28 12:19 作者: 結(jié)果 時(shí)間: 2025-3-28 18:23 作者: EXULT 時(shí)間: 2025-3-28 22:18
Joseph Krau?,Martin Berger,Walter Helmersulfate chain. The HN3 and HS20 antibodies inhibit Wnt/Yap signaling and suppress HCC cell growth. To improve anti-tumor efficacy, anti-GPC3 immunotoxins and CAR-T cell therapies have been developed. The Wnt-blocking HN3 immunotoxin is more potent than YP7 immunotoxin. With an engineered toxin, the H作者: 反復(fù)無(wú)常 時(shí)間: 2025-3-29 00:52 作者: Thyroxine 時(shí)間: 2025-3-29 03:31 作者: Conflagration 時(shí)間: 2025-3-29 07:22 作者: septicemia 時(shí)間: 2025-3-29 14:51
Joseph Krau?,Martin Berger,Walter Helmerss provided by Society for Immunotherapy of Cancer, for recommending adjuvant immunotherapy in surgically-treated stage II as well as stage III melanoma patients. Adjuvant radiotherapy is also discussed in the chapter along with the risk factors described by various researchers that indicate the requ
